Altman Testimony, Huang Joins Trump China Visit, & More
Key developments covered include OpenAI CEO Sam Altman testifying in the Musk lawsuit, where he criticized Musk's management style. Furthermore, Nvidia CEO Jensen Huang's participation in President Trump's visit to China was confirmed, despite earlier reports of uncertainty. Politically, FDA Commissioner Marty Makary resigned, with Kyle Diamantas stepping in as the acting commissioner. Economically, the domestic box office reported a substantial weekend gain of $161.2 million, signaling robust consumer spending in the entertainment sector.
Ad slot
Key updates across tech, politics, and markets dominated the morning session, featuring Sam Altman's testimony, Jensen Huang's confirmed trip to China, and FDA leadership changes.
OpenAI CEO Sam Altman Testifies in Musk Lawsuit
OpenAI CEO Sam Altman took the stand in the trial concerning the lawsuit filed by Elon Musk against OpenAI. During his testimony, Altman offered critiques of Musk's management style and addressed his own departure from the company.
Critique of Management: Altman described Tesla CEO Elon Musk's management style as "demotivated."
Departure Context: He stated that his exit from the startup was a "morale boost" and suggested Musk did not understand "how to run a good research lab."
Board Action: Altman also testified that he was "completely caught off guard" when the OpenAI board briefly removed him as CEO in 2023.
Nvidia CEO Huang Confirmed for Trump's China Visit
Nvidia confirmed that CEO Jensen Huang will join the group of executives traveling to China during President Donald Trump's visit. This confirmation followed initial uncertainty regarding his participation.
Ad slot
Initial Uncertainty: Huang's name was not initially listed among the CEOs joining the U.S. delegation provided by the White House.
Confirmation: Trump publicly stated that Huang was aboard Air Force One, denying any exclusion from the trip.
Company Stance: An Nvidia spokesperson noted that Huang is joining the trip "to support America and the administration's goals." Shares of the chipmaker rose by over 2% before the market opened.
FDA Leadership Transition in Washington D.C.
President Trump announced the resignation of Dr. Marty Makary as Commissioner of the Food and Drug Administration (FDA). Kyle Diamantas, a former senior food official at the agency, has been appointed as the acting commissioner.
Significance: Makary's departure concludes a period marked by internal disagreements and leadership instability at the FDA.
Political Context: Reports indicated that Health and Human Services Secretary Robert F. Kennedy Jr. was involved in the decision to replace him.
Box Office Sees Strong Weekend Gains
The domestic movie box office reported significant revenue over the past weekend, indicating strong consumer spending in entertainment.
Weekend Performance: The box office generated $161.2 million in ticket sales, marking an increase of nearly 88% compared to the previous year.
Year-to-Date: For 2026, the box office has accumulated just over $3 billion through Sunday, representing a 16% year-over-year increase, though remaining below 2019 levels.
Top Performers: "The Devil Wears Prada 2," "Mortal Kombat II," and "Michael" led the weekend's box office receipts.
